[{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0.17999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ J.P. Morgan","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ J.P. Morgan"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"TYK","graph1":"Oncology","graph2":"Approved","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medison Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Medison Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Specialised Therapeutics \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT proto-oncogene receptor tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ripretinib","moa":"KIT","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Specialised Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Specialised Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Specialised Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Specialised Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"GENESIS Pharma","sponsor":"Deciphera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"GENESIS Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GENESIS Pharma \/ Deciphera Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"GENESIS Pharma \/ Deciphera Pharmaceuticals"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":2.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"Tablet","sponsorNew":"Deciphera Pharmaceuticals \/ ONO Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ ONO Pharmaceutical"},{"orgOrder":0,"company":"Deciphera Pharmaceuticals","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Ripretinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Deciphera Pharmaceuticals","amount2":2.3999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":2.3999999999999999,"dosageForm":"","sponsorNew":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Deciphera Pharmaceuticals \/ Ono Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals for Ripretinib

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the acquisition, the company will utilize Deciphera's pipeline and approved products, which include Qinlock (ripretinib), indicated for treating advanced gastrointestinal stromal tumor.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : $2,400.0 million

                          June 11, 2024

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ono Pharmaceutical

                          Deal Size : $2,400.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Through the acquisition, the company will utilize Deciphera's pipeline and approved products, which include Qinlock (ripretinib), indicated for treating fourth-line gastrointestinal stromal tumors.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : $2,400.0 million

                          April 29, 2024

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ono Pharmaceutical

                          Deal Size : $2,400.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, GENESIS Pharma will exclusively commercialize Qinlock (ripretinib) for the treatment of fourth-line gastrointestinal stromal tumor.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 12, 2024

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Deciphera Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Qinlock (ripretinib), recently approved in Singapore, is an orally administered switch-control kinase inhibitor developed for the treatment of GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 07, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Qinlock (ripretinib) is an orally administered switch-control kinase inhibitor developed for the treatment of gastrointestinal stromal tumor, or GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 14, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Qinlock (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases, involved in GIST, by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 20, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : QINLOCK (Ripretinib) is an orally administered switch-control kinase inhibitor developed for the treatment of gastrointestinal stromal tumor, or GIST. Ripretinib improves GIST treatment by inhibiting the full spectrum known mutations in KIT and PDGFRA.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 03, 2023

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : QINLOCK (ripretinib) is a switch-control tyrosine kinase inhibitor that was engineered to broadly inhibit KIT and PDGFRA mutated kinases by using a dual mechanism of action that regulates the kinase switch pocket and activation loop.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 10, 2022

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Efficacy observed with QINLOCK (ripretinib) tyrosine kinase inhibitor, was comparable to sunitinib with a more favorable safety and tolerability profile in GIST patients previously treated with Imatinib.

                          Brand Name : Qinlock

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 24, 2022

                          Lead Product(s) : Ripretinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank